Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T19947
|
|||||
Target Name |
Immunoproteasome complex (IP)
|
|||||
Synonyms |
i-proteasome complex
Click to Show/Hide
|
|||||
Gene Name |
NO-GeName
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Idiopathic inflammatory myopathy ICD-11: 4A41 | |||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
1 | KZR-616 | Drug Info | Phase 2 | Dermatomyositis | [2] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Inhibitor | [+] 30 Inhibitor drugs | + | ||||
1 | KZR-616 | Drug Info | [3] | |||
2 | Peptide analog 10 | Drug Info | [1] | |||
3 | Peptide analog 12 | Drug Info | [1] | |||
4 | Peptide analog 15 | Drug Info | [1] | |||
5 | Peptide analog 16 | Drug Info | [1] | |||
6 | Peptide analog 18 | Drug Info | [1] | |||
7 | Peptide analog 20 | Drug Info | [1] | |||
8 | Peptide analog 22 | Drug Info | [1] | |||
9 | Peptide analog 24 | Drug Info | [1] | |||
10 | Peptide analog 26 | Drug Info | [1] | |||
11 | Peptide analog 29 | Drug Info | [1] | |||
12 | Peptide analog 30 | Drug Info | [1] | |||
13 | Peptide analog 32 | Drug Info | [1] | |||
14 | Peptide analog 35 | Drug Info | [1] | |||
15 | Peptide analog 40 | Drug Info | [1] | |||
16 | Peptide analog 42 | Drug Info | [1] | |||
17 | Peptide analog 43 | Drug Info | [1] | |||
18 | Peptide analog 9 | Drug Info | [1] | |||
19 | PMID29865878-Compound-38 | Drug Info | [1] | |||
20 | PMID29865878-Compound-39 | Drug Info | [1] | |||
21 | PMID29865878-Compound-40 | Drug Info | [1] | |||
22 | PMID29865878-Compound-41 | Drug Info | [1] | |||
23 | PMID29865878-Compound-42 | Drug Info | [1] | |||
24 | PMID29865878-Compound-45 | Drug Info | [1] | |||
25 | PMID29865878-Compound-47 | Drug Info | [1] | |||
26 | PMID29865878-Compound-50 | Drug Info | [1] | |||
27 | PMID29865878-Compound-52 | Drug Info | [1] | |||
28 | PMID29865878-Compound-54 | Drug Info | [1] | |||
29 | PMID29865878-Compound-56 | Drug Info | [1] | |||
30 | PMID29865878-Compound-60 | Drug Info | [1] |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. | |||||
REF 2 | ClinicalTrials.gov (NCT04628936) An Open-label Extension to the Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients With Active Polymyositis or Dermatomyositis. U.S.National Institutes of Health. | |||||
REF 3 | Zetomipzomib (KZR-616) attenuates lupus in mice via modulation of innate and adaptive immune responses. Front Immunol. 2023 Mar 10;14:1043680. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.